Genscript Biotech Co. (OTCMKTS:GNNSF – Get Free Report) dropped 21.1% during trading on Thursday . The company traded as low as C$1.50 and last traded at C$1.50. Approximately 300 shares traded hands during trading, a decline of 95% from the average session volume of 6,289 shares. The stock had previously closed at C$1.90.
Genscript Biotech Stock Performance
The firm has a fifty day simple moving average of C$1.64 and a two-hundred day simple moving average of C$1.64.
Genscript Biotech Company Profile
GenScript Biotech Corporation is a global contract research, development and manufacturing organization (CDMO) specializing in synthetic biology and biopharmaceutical services. Founded in 2002, the company provides end-to-end solutions that span gene and peptide synthesis, recombinant protein expression, custom antibody discovery and cell line development. GenScript’s integrated platforms support early-stage discovery through to process development, enabling academic institutions, biotech innovators and pharmaceutical companies to accelerate research timelines.
The company’s core offerings include molecular biology services such as DNA construction, gene editing using CRISPR/Cas9 technology and high-throughput peptide libraries.
Further Reading
- Five stocks we like better than Genscript Biotech
- Starbucks Builds Sovereign AI to Cut $400 Million in Software Costs
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
Receive News & Ratings for Genscript Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genscript Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
